Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation
Prostaglandins are lipid-derived autacoids that modulate many physiological systems
including the CNS, cardiovascular, gastrointestinal, genitourinary, endocrine, respiratory�…
including the CNS, cardiovascular, gastrointestinal, genitourinary, endocrine, respiratory�…
The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic�…
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic�…
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
AN Hata, MJ Niederst, HL Archibald…�- Nature medicine, 2016 - nature.com
Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known�…
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known�…
[HTML][HTML] Emerging insights into targeted therapy-tolerant persister cells in cancer
HF Cabanos, AN Hata�- Cancers, 2021 - mdpi.com
Simple Summary Acquired resistance to molecularly targeted therapies remains a major
challenge in the treatment of cancer. It has been hypothesized that drug-tolerant (or�…
challenge in the treatment of cancer. It has been hypothesized that drug-tolerant (or�…
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective�…
Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cycling cancer persister cells arise from lineages with distinct programs
Non-genetic mechanisms have recently emerged as important drivers of cancer therapy
failure, where some cancer cells can enter a reversible drug-tolerant persister state in�…
failure, where some cancer cells can enter a reversible drug-tolerant persister state in�…
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK�…
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small�…
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small�…
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee…�- Cancer discovery, 2015 - AACR
Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…
[HTML][HTML] A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Single-cell genomics is essential to chart tumor ecosystems. Although single-cell RNA-Seq
(scRNA-Seq) profiles RNA from cells dissociated from fresh tumors, single-nucleus RNA�…
(scRNA-Seq) profiles RNA from cells dissociated from fresh tumors, single-nucleus RNA�…
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical
problem. Although many drivers of acquired drug resistance have been identified,,–, the�…
problem. Although many drivers of acquired drug resistance have been identified,,–, the�…